GlassScriptPhysician profile
Ashley M Glaser
NPI 1437711470
$4,431.30
in general payments reported to CMS, 2019-2025
25 companies · $764 in 2025
The $764 reported for 2025 was more than what 81% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $887 · 2022: $1,097 · 2023: $648 · 2024: $1,034 · 2025: $764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,249 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,249.02 |
| Education | $198.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aspira Women'S Health INC | $858.36 | 2021-2024 | Ova1 |
| Astellas Pharma US INC | $600.05 | 2022-2025 | Veozah |
| Mayne Pharma Commercial LLC | $537.07 | 2021-2025 | |
| Abbvie INC. | $390.86 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $317.96 | 2021-2025 | |
| Exeltis, USA INC. | $271.79 | 2021-2025 | Slynd |
| Biogen, INC. | $234.42 | 2024-2025 | Zurzuvae |
| Daiichi Sankyo INC. | $223.01 | 2021-2022 | |
| Myovant Sciences INC. | $147.51 | 2021-2022 | |
| Abbott Laboratories | $123.45 | 2025 | Cardiomems |
| Organon LLC | $122.62 | 2022-2024 | Nexplanon |
| Shield Therapeutics INC | $99.24 | 2023-2024 | Accrufer |
| Agile Therapeutics, INC. | $98.68 | 2021-2022 | |
| Millicent US INC | $68.62 | 2023-2025 | Intrarosa, Femlyv, Femring |
| Sumitomo Pharma America, INC. | $65.65 | 2025 | Myfembree |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $61.01 | 2021-2024 | Paragard T 380a, Paragard T 380a |
| Channel Medsystems, INC. | $42.47 | 2024 | |
| Therapeuticsmd, INC. | $33.76 | 2021-2022 | |
| Evofem Biosciences, INC. | $26.33 | 2021 | |
| Scynexis, INC. | $25.46 | 2021-2022 | |
| Octapharma USA, INC. | $25.07 | 2024 | Balfaxar |
| Hologic Sales and Service, LLC | $17.95 | 2023 | Aptima |
| Medtronic, INC. | $14.23 | 2023 | Truclear |
| Olympus America INC. | $13.54 | 2023 | Olympus |
| Mylan Pharmaceuticals INC. | $12.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Glaser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.